Regulus Therapeutics Inc

-0.05 (-5.46%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)64.82M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.02 Million
Adjusted EPS-$0.09
See more estimates
10-Day MA$1.10
50-Day MA$1.42
200-Day MA$1.01
See more pivots

Regulus Therapeutics Inc Stock, NASDAQ:RGLS

4224 Campus Point Court, Suite 210, San Diego, California 92121
United States of America
Phone: +1.858.202.6300
Number of Employees: 24


Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.